These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 30575598)

  • 21. Major unanswered questions in the clinical gout field.
    Stamp LK
    Curr Opin Rheumatol; 2017 Mar; 29(2):171-177. PubMed ID: 27926541
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A survey on the beliefs and knowledge of gout management in new medical graduates - New South Wales, Australia.
    Terrill M; Riordan J
    Int J Rheum Dis; 2018 Feb; 21(2):517-522. PubMed ID: 28544467
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dyslipidemia, Alcohol Consumption, and Obesity as Main Factors Associated With Poor Control of Urate Levels in Patients Receiving Urate-Lowering Therapy.
    Latourte A; Bardin T; Clerson P; Ea HK; Flipo RM; Richette P
    Arthritis Care Res (Hoboken); 2018 Jun; 70(6):918-924. PubMed ID: 28834411
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Medication adherence in gout: a systematic review.
    De Vera MA; Marcotte G; Rai S; Galo JS; Bhole V
    Arthritis Care Res (Hoboken); 2014 Oct; 66(10):1551-9. PubMed ID: 24692321
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patients with Gout Treated with Conventional Urate-lowering Therapy: Association with Disease Control, Health-related Quality of Life, and Work Productivity.
    Wood R; Fermer S; Ramachandran S; Baumgartner S; Morlock R
    J Rheumatol; 2016 Oct; 43(10):1897-1903. PubMed ID: 27036386
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Medication adherence among patients with gout: A systematic review and meta-analysis.
    Scheepers LEJM; van Onna M; Stehouwer CDA; Singh JA; Arts ICW; Boonen A
    Semin Arthritis Rheum; 2018 Apr; 47(5):689-702. PubMed ID: 29198878
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Monitoring of Urate-Lowering Therapy Among US Veterans Following the 2012 American College of Rheumatology Guidelines for Management of Gout.
    Hughes JC; Wallace JL; Bryant CL; Salvig BE; Fourakre TN; Stone WJ
    Ann Pharmacother; 2017 Apr; 51(4):301-306. PubMed ID: 27881692
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comprehensive dietary education in treated gout patients does not further improve serum urate.
    Holland R; McGill NW
    Intern Med J; 2015 Feb; 45(2):189-94. PubMed ID: 25495503
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The gouty tophus: a review.
    Chhana A; Dalbeth N
    Curr Rheumatol Rep; 2015 Mar; 17(3):19. PubMed ID: 25761926
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic factors associated with early gout flare recurrence in patients initiating urate-lowering therapy during an acute gout flare.
    Janssen CA; Oude Voshaar MAH; Ten Klooster PM; Vonkeman HE; van de Laar MAFJ
    Clin Rheumatol; 2019 Aug; 38(8):2233-2239. PubMed ID: 31030363
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Update on emerging urate-lowering therapies.
    Chohan S; Becker MA
    Curr Opin Rheumatol; 2009 Mar; 21(2):143-9. PubMed ID: 19339925
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Significance of the initiation time of urate-lowering therapy in gout patients: A retrospective research.
    Feng X; Li Y; Gao W
    Joint Bone Spine; 2015 Dec; 82(6):428-31. PubMed ID: 26456042
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum urate as surrogate endpoint for flares in people with gout: A systematic review and meta-regression analysis.
    Stamp L; Morillon MB; Taylor WJ; Dalbeth N; Singh JA; Lassere M; Christensen R
    Semin Arthritis Rheum; 2018 Oct; 48(2):293-301. PubMed ID: 29566967
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New therapeutic approach to hyperuricemia and gout in the light of recommendations.
    Lioté F
    Joint Bone Spine; 2016 Jul; 83(4):376-80. PubMed ID: 27085801
    [No Abstract]   [Full Text] [Related]  

  • 35. Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial.
    Doherty M; Jenkins W; Richardson H; Sarmanova A; Abhishek A; Ashton D; Barclay C; Doherty S; Duley L; Hatton R; Rees F; Stevenson M; Zhang W
    Lancet; 2018 Oct; 392(10156):1403-1412. PubMed ID: 30343856
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cardiac and renal protective effects of urate-lowering therapy.
    Richette P; Latourte A; Bardin T
    Rheumatology (Oxford); 2018 Jan; 57(suppl_1):i47-i50. PubMed ID: 29272510
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rationale and design of the randomized evaluation of an Ambulatory Care Pharmacist-Led Intervention to Optimize Urate Lowering Pathways (RAmP-UP) Study.
    Coburn BW; Cheetham TC; Rashid N; Chang JM; Levy GD; Kerimian A; Low KJ; Redden DT; Bridges SL; Saag KG; Curtis JR; Mikuls TR
    Contemp Clin Trials; 2016 Sep; 50():106-15. PubMed ID: 27449546
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Primary care providers' knowledge, beliefs and treatment practices for gout: results of a physician questionnaire.
    Harrold LR; Mazor KM; Negron A; Ogarek J; Firneno C; Yood RA
    Rheumatology (Oxford); 2013 Sep; 52(9):1623-9. PubMed ID: 23620554
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pegloticase for treating refractory chronic gout.
    George RL; Sundy JS
    Drugs Today (Barc); 2012 Jul; 48(7):441-9. PubMed ID: 22844655
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Limitations of the Current Standards of Care for Treating Gout and Crystal Deposition in the Primary Care Setting: A Review.
    Keenan RT
    Clin Ther; 2017 Feb; 39(2):430-441. PubMed ID: 28089200
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.